“…The clinical effectiveness of efBDP-FOR in asthma patients requiring combination ICS-LABA therapy is well established. 12–16,21–27,46,47 However, to our knowledge, no studies have evaluated both the clinical and cost effectiveness of switching from another ICS-LABA combination to efBDP-FOR in the typical asthma patient — a scenario that is likely to be increasingly common in primary care, given the substantially lower cost and comparable effectiveness of the efBDP-FOR inhaler and, in the UK, certain NHS recommendations to physicians. 2…”